Table1.
Multivariate analysis of Disease Free Survival in patients with stage II and III CRC from the clinical cohort.
| Stage II + III | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Covariate | HR | 95% CI | P-value | HR | 95% CI | P-value |
| *Age (>Median (66) vs <Median) | 1.02 | 0.65–1.61 | 0.93 | - | - | - |
| Gender (Male vs Female) | 1.02 | 0.64–1.62 | 0.94 | - | - | - |
| *Tumor size(>45mm vs <45mm) | 1.08 | 0.66–1.76 | 0.76 | - | - | - |
| Vascular Invasion (Positive vs Negative) | 1.29 | 0.74–2.49 | 0.47 | - | - | - |
| Mucinous (Positive vs Negative) | 1.36 | 0.64–2.62 | 0.32 | - | - | - |
| Perineural Invasion (Positive vs Negative) | 1.87 | 1.01–3.45 | 0.046 | 1.73 | 0.89–3.34 | 0.11 |
| Lymph node (Positive vs Negative) | 1.89 | 1.14–3.12 | 0.014 | 2.17 | 1.06–4.46 | 0.034 |
| TFAP2E methylation (high vs low) | 1.81 | 1.10–2.98 | 0.019 | 1.91 | 1.02–3.58 | 0.045 |
| Stage II | Univariate | Multivariate | ||||
| Covariate | HR | 95% CI | P-value | HR | 95% CI | P-value |
| *Age (>Median (66) vs <Median) | 0.66 | 0.27–1.63 | 0.37 | |||
| Gender (Male vs Female) | 0.76 | 0.32–1.78 | 0.53 | - | - | - |
| *Tumor size(>45mm vs <45mm) | 0.89 | 0.35–2.25 | 0.79 | - | - | - |
| Mucinous (Positive vs Negative) | 0.8 | 0.18–3.47 | 0.77 | - | - | - |
| Perineural Invasion (Positive vs Negative) | 1.5 | 0.46–4.86 | 0.49 | - | - | - |
| Vascular Invasion (Positive vs Negative) | 2.17 | 0.67–7.05 | 0.2 | 2.11 | 0.59–7.51 | 0.25 |
| TFAP2E methylation (high vs low) | 3.14 | 1.09–9.01 | 0.035 | 1.91 | 1.20–25.95 | 0.029 |
Abbreviations: HR: Hazard Ratio; CI : Confidence Interval; * Median values used. TFAP2E methylation (high >40%; low ≤40%)